UNSPSC 51272104: Butethamine

This classification denotes an anesthetic agent with the molecular formula C13H20N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M63DKI91K, chemically known as 2-isobutylaminoethanol hydrochloric acid salt, p-aminobenzoic acid ester but generally known as butethamine hydrochloride, which bears US NIH Compound Identifier 11116. As of Q4 2014, BUTETHAMINE remains the US FDA Preferred Term for this commodity. Butethamine bears US NLM identifiers UMLS ID C0301287 and NCI Concept Code C83566.

SMILES: CC(C)CNCCOC(=O)C1=CC=C(C=C1)N.Cl.

UNSPSC 51272104 Butethamine is a Commodity code that in recent state and local procurement activity denotes pharmaceuticals and related products supplied to public health and human services agencies. Butethamine, a local anesthetic, appears in solicitations alongside naloxone, generic pharmaceuticals, and over-the-counter products procured by county health departments, state health and human services commissions, and multistate cooperative purchasing alliances to support community health initiatives, emergency response programs, and state employee pharmacy benefit plans. State and local governments acquire these products through competitive bidding and cooperative purchasing vehicles, with vendors required to maintain cGMP and Drug Supply Chain Security Act compliance, establish relationships with authorized pharmaceutical wholesalers, and meet insurance and regulatory standards. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon).

Geographic activity concentrates in Florida, Texas, and Minnesota. Representative recent opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries and a response deadline of July 26, 2023; the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, gathering market intelligence on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802, posted January 20, 2026, establishing multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities with a proposals deadline of March 26, 2026 and contract effectiveness of July 1, 2026. Vendors must submit detailed product information including National Drug Codes, maintain relationships with authorized wholesalers, and comply with administrative fee structures and performance penalty thresholds ranging from $200 to $1,500 per violation.